29th January – 1st February 2018 | Paris, France

REGISTER NOW – SAVE €200

Speakers

Expand/Collapse

Adam Hacker
VP, Head of Vaccines and Microbiome, Global Regulatory Affairs
Janssen Pharmaceuticals

Adam Hacker has twenty years of regulatory experience and has worked at Janssen Pharmaceuticals (a Johnson & Johnson company) since 2008 and was appointed Vice President and Head of Vaccines and subsequently head of Scientific Innovation Projects for the Global Regulatory Affairs (GRA) organization in June 2015. Adam is responsible for coordinating regulatory activities for all microbiome-related projects and establishing policy positions and working closely with the Janssen Human Microbiome Institute. Adam has a PhD in developmental molecular biology from the National Institute of Medical Research, Mill Hill, London.  

Day One

Tuesday, 30th January 2018

17.40 | Panel Presentation: Overcoming Regulatory Uncertainty to Accelerate Speed to Market

Outi Vaarala
VP Head of Translational Biology
AstraZeneca

Outi Vaarala is vice-president and head of lung immunity department in respiratory, inflammations and autoimmunity, innovative medicines, at AstraZenenca in Gothenburg. Her department is responsible for biological research, ranging from target identification to Phase 2 projects, including the invention of biomarkers for personalized treatments. Dr Vaarala is a medical doctor and a professor of pediatric immunology. She has published more than 200 peer-reviewed articles in scientific journals in the field of immunology

Day Two

Wednesday, 31st January 2018

15.20 | Panel Presentation: Committing to the Therapeutic Potential of the Microbiome - Resources for Results

14.20 | Gut Microbiota Composition, Short-Chain Fatty Acids and Regulatory T-Cell – Are We Ready to Translate into Therapeutics?

Assaf Oron
Chief Business Officer
BiomX

Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity.  At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Day Two

Wednesday, 31st January 2018

10.20 | Novel Approaches for Microbiome Modulation Addressing IBD, Cancer and Acne

Luc Sterkman
CEO
Caelus Health

Day One

Tuesday, 30th January 2018

17.40 | Panel Presentation: Overcoming Regulatory Uncertainty to Accelerate Speed to Market

13.10 | FMT-Based Discovery: From Platform to Product

Bharat Dixit
VP Bioprocessing and Manufacturing
Crestovo

Bharat Dixit leads all production, method development and quality assurance efforts for Crestovo. Dr. Dixit has more than 11 years of experience in the biopharmaceutical industry, developing complex biologics. Most recently, Dr. Dixit led the analytical and formulation development group at Genocea Biosciences, where he was involved in the development of HSV-2 and Streptococcus pneumoniae vaccines. Prior to Genocea, Dr. Dixit held positions at Formatech, Inc. and Sanofi Pasteur. Dr. Dixit completed his post-doctoral research at the University of Massachusetts Medical School, Worcester and University of Texas Medical Branch at Galveston, and earned his Ph.D. in biochemistry from the Institute of Microbial Technology, India.

Day Two

Wednesday, 31st January 2018

09.00 | Panel Presentation: Manufacturing the Microbiome - An Industry Perspective

Jean de Gunzburg
Chief Scientific Officer
DaVolterra

Jean de Gunzburg is the Chief Scientific Officer of Da Volterra, an emerging biotechnology company, headquartered in Paris, France. It is committed to the discovery and development of innovative approaches to control the deleterious consequences of antibiotic treatments such as emergence and dissemination of antibiotic resistance or Clostridium difficile infections, as well as long term consequences of antibiotic overuse such as allergy, metabolic diseases and obesity. Da Volterra’s mission is to tackle these worldwide dramatic issues through the application of its proprietary technologies and products. Prior to this, Jean de Gunzburg led an academic research career in molecular and cell biology at the Institut Pasteur (Paris, France), the Whitehead Institute for Biomedical Research (Cambridge, MA, USA) and the Institut Curie (Paris, France). He is the author of over 70 publications in international peer-reviewed scientific journals, and continues to serve on several grant review committees.

Day One

Tuesday, 30th January 2018

15.50 | Preserving the Intestinal Microbiota during Antibiotic Treatments with DAV132: From Preclinical Studies in Hamsters to Phase 1 Trials in Humans

Confirmed Company
TBA
Enterome

Day One

Tuesday, 30th January 2018

11.00 | Drugs from Bugs – Using Metagenomic Dataset Delivers Druggable Targets

James McIlroy
CEO
Enterobiotix

James McIlroy is a final year medical student at the University of Aberdeen and CEO of EnteroBiotix, a biotechnology company focused on using microbial communities derived directly from the human gastrointestinal tract to prevent and treat disease. Alongside his studies, he has raised over £700k in funding for the company to establish an integrated GMP-compliant manufacturing facility and a product pipeline. He was awarded an Enterprise Fellowship by the Royal Society of Edinburgh in 2016 and a Visiting Research Fellowship by United European Gastroenterology in 2017.

Day Two

Wednesday, 31st January 2018

11.50 | Novel Approaches to an Ancient Therapeutic Strategy

Kristin Wannerberger
Director R&D Alliance Management
Ferring Pharmaceuticals

Day One

Tuesday, 30th January 2018

17.40 | Panel Presentation: Overcoming Regulatory Uncertainty to Accelerate Speed to Market

Day Two

Wednesday, 31st January 2018

15.20 | Panel Presentation: Committing to the Therapeutic Potential of the Microbiome - Resources for Results

Daniel van der Lelie
Chief Scientific Officer
Gusto Global

Dr. Daniel van der Lelie is the Chief Scientific Officer and Co-Founder of Gusto Global, a leading microbiome drug discovery and development company focused on the rational design of live biotherapeutics that modulate the immune system.  Dr. van der Lelie has worked in senior management roles in biotechnology, agriculture, environmental sciences and on the interface between biological sciences and nanotechnology throughout his career.  Prior to founding Gusto Global, he was the Global Director of Ag BioSolutions R&D at FMC Corporation.   Dr. van der Lelie’s position at FMC resulted from the company’s acquisition of the Center for Agriculture and Environmental Biotechnology, a business unit founded by Dr. van der Lelie at Research Triangle Institute. Prior to FMC and RTI, Dr. van der Lelie was the founder of the microbiology group and the co-founder of the group for bioinspired assembly of nanomaterials at Brookhaven National Laboratory. Dr. van der Lelie’s research has resulted in more than 150 publications in peer reviewed journals, including PLoS ONE, PLoS Genetics, Nature, Nature Chemistry, Nature Nanotechnology and Nature Biotechnology, and 21 patents / patent applications.

Day One

Tuesday, 30th January 2018

10.00 | State-of-the-Art Functional Analysis of Microbial Communities

Jim Brown
Director, Computational Biology & Senior Fellow
GSK

Responsible for the managing bioinformatics for: 1) Oncology Therapeutic Area including immuno-oncology; 2) Infectious Disease Therapeutic Area Unit including antivirals, antibacterials & host defense; 3) Diseases of the Developing World including TB, malaria and kinetoplastid therapeutics and; 4) Microbiome Collaborative Network which is leading the application of human microbiome studies to drug discovery. Elected as GSK Senior R&D Fellow in 2016.

Day Two

Wednesday, 31st January 2018

15.20 | Panel Presentation: Committing to the Therapeutic Potential of the Microbiome - Resources for Results

14.50 | Respiratory Tract and Gut Microbiomes in Precision Medicine for Respiratory Diseases

Rachel Teitelbaum
CEO
Hervana Bio

Rachel Teitelbaum, Ph.D. is the founder and CEO of Hervana Bio, LTD.  Earning her Ph.D. in microbiology and immunology in the laboratory of Barry R. Bloom.  Dr. Teitelbaum has extensive experience in R&D in infectious disease and vaccine development and modelling host-microbe interface interactions.  She is also a partner in an IP firm, having served as a  Patent Agent registered to practice before the United States and Israeli Patent and Trademark Offices.

Day Two

Wednesday, 31st January 2018

12.30 | Harnessing the Vaginal Microbiome in Contraceptive Development

Alexander Sulakvelidze
Chief Scientific Officer
Intralytix, Inc.

Dr. Alexander “Sandro” Sulakvelidze, Ph.D., is an Executive Vice-President and Chief Scientific Officer of Intralytix, Inc.  Dr. Sulakvelidze is an internationally recognized expert in phage technology and infectious disease epidemiology.  He has published extensively on the subjects of phage biocontrol and phage therapy, and he is the author of several issued and pending patents in the field of bacteriophages.  Dr. Sulakvelidze also co-edited a major book about bacteriophages, which was published by the CRC Press in 2005.

Day Two

Wednesday, 31st January 2018

10.50 | Modulating Human Microbiome: Bacteriophages and Their Practical Applications

Greg Sieczkiewicz
Managing Director, Chief IP Counsel
MPM Capital

Lars Engstrand
Professor
Karolinska Institutet

Professor Lars Engstrand has more than 30 years experience as a clinical microbiologist. His research interest includes the pathophysiology, diagnosis and treatment of gastrointestinal infections and studies on cellular interactions and pathogenesis particularly in the context of Helicobacter pylori infections. In a number of studies, population-based epidemiology has been combined with clinical and basic microbiological science, including molecular biology and genomics. Similar approaches have been applied on studies of the human microbiome in health and disease where he initiated the use of next generation sequencing technology in studies of the human gut microbiome. Cross-departmental collaborations have been developed with a number research centers in Europe and the US. He is Director of the Clinical Genomics facility and the Centre for Translational Microbiome Research at Science for Life Laboratory/Karolinska Institute in Stockholm.

Day One

Tuesday, 30th January 2018

09.30 | Definition of a Healthy Microbiome and If Disturbed - How to Shape It Back to Normal

Les Tillack
CEO
Luina Bio

Working for Progen Pharmaceuticals for 11 years prior to becoming CEO of LuinaBio (previously PharmaSynth) in 2009. During his time at Progen, Les has worked with and overseen Progen’s anti-cancer drug PI-88s progression from preclinical to phase 3 manufacture. He has also been responsible for the tech transfer and manufacture of many client products for both clinical applications and marketed products. Les holds a Bachelor of Science in microbiology and a Bachelor of Engineering in Chemical Engineering. Prior to commencing with Progen, Les spent 11 years working in clinical pathology for Drs Sullivan and Nicolaides Pathologists and has worked on various research projects for both the Department of Primary Industries and the University of Queensland.

Olga Danilchanka
Microbiome Lead; Exploratory Science Center (ESC)
Merck

Day Two

Wednesday, 31st January 2018

15.20 | Panel Presentation: Committing to the Therapeutic Potential of the Microbiome - Resources for Results

13.50 | The Microbiome: Translating Research into Discovery

Dario Gutierrez
Immuno-Biology Lead
Merck

Lee Jones
CEO
Rebiotix

Lee Jones is the founder, president, and chief executive officer of Rebiotix, a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome. Lee has over 30 years of experience as a medical technology executive and entrepreneur in large and small companies and academia. With Rebiotix as her first foray into biotechnology, Lee is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy (MRT). The company’s first MRT is a biologic drug targeted at recurrent Clostridium difficile infection.

Day One

Tuesday, 30th January 2018

17.40 | Panel Presentation: Overcoming Regulatory Uncertainty to Accelerate Speed to Market

13.50 | Rollercoaster Ride for the Pioneers in Microbiome Clinical Program Development

Magali Cordaillat-Simmons
Scientific and Regulatory Affairs Director
Pharmabiotic Research Institute

Magali Cordaillat-Simmons earned her PhD in 2005 at Descartes, France, in Cardiovascular Pharmacology. She then worked as a Research Associate at the University of Virginia, VA, USA, where she studied the influence of epigenetics on renin expression. Today, she works as the Executive Scientist at the Pharmabiotic Research Institute (PRI), located in Aurillac, France. This association is dedicated to supporting companies in the development of medicinal probiotics in Europe. She currently supervises the association analysis of the European Pharmaceutical Legislation and the association regulatory activities so Pharmabiotics become a therapeutic reality in Europe.

Day One

Tuesday, 30th January 2018

17.40 | Panel Presentation: Overcoming Regulatory Uncertainty to Accelerate Speed to Market

17.10 | The Regulatory Challenge for Registering Live Biotherapeutic Products in Europe

Massimo Mazorati
Co-founder
ProDigest

Massimo Marzorati graduated in 2003 from the University of Milan (Italy) in Biotechnology. In 2007 he obtained a PhD degree in the field of microbial ecology at the University of Milan. In 2007 he started as a post-doctoral researcher at LabMET, Ghent University (Belgium). His main research interest is the interaction between intestinal bacteria and human health. This includes pro- and prebiotics, microbial metabolism and bioavailability of food compounds and pharmaceuticals and the relation between the structure of the intestinal microbiota and its resilience under changing environmental conditions. In 2008, he founded ProDigest, a spin-off company from Ghent University, which provides customized services in the field of gastrointestinal transit, bioavailability and metabolism, to the operators in the food, feed and pharmaceutical industry.

Day One

Tuesday, 30th January 2018

13.40 | Delivery, Survival, Engraftment and Activity of LBPs in the Gastrointestinal Tract

Laurence Zitvogel
Professor
Institut Gustave Roussy

Prof. Laurence Zitvogel, M.D. serves as Research Director at INSERM U1015, Gustave Roussy Cancer Center, Villejuif, France (Institut National de la Santé et de la Recherche Médicale). Prof. Zitvogel has been an Oncologist and Researcher of Institut Gustave Roussy since 1995. She has been an Independent Director of Transgene SA since June 19, 2013. She serves as a Member of Scientific Advisory Board at Neovacs S.A. She serves as a Member of Scientific and Clinical Board at Invectys SA. She is Chevalier de la Légion d'Honneur. Prof. Zitvogel is a Co-Director of the Center of Clinical Investigations of Biotherapies. She is a Member of the Académie de Médecine. Prof. Zitvogel is Professor of immunology and biology at Paris University (Université de Paris Sud). She is internationally renowned for her work in anti-tumor immunology. She has led Phase 1 and Phase 2 clinical studies in cancer immunotherapy and deciphered the mechanisms of immunogenic tumor death triggered by cytotoxic agents used in oncology. She holds numerous prizes and awards (amongst them the INSERM Research Prize).

John Aunins
EVP of Manufacturing and Chief Technology Officer
Seres Therapeutics

John Aunins is the Executive Vice President of Bioprocess & Manufacturing and the Chief Technology Officer of Seres. He has more than 26 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing support, and project leadership. Prior to joining Seres, he led process and product development teams at Merck Research Laboratories for Vaqta®, Varivax®, Zostavax®, ProQuad®, Rotateq®, and Gardasil®. The Vaqta and Gardasil process teams were awarded with ACS Industrial Biotechnology Awards for innovation, contribution to bioengineering, and societal impact. He is a Fellow of the American Institute for Medical and Biological Engineering, and an adjunct Full Professor at the Instituto de Tecnologia Química e Biológica (ITQB) in Oeiras, Portugal. He has authored over 50 articles and book chapters, and has chaired five international conferences in vaccines and bioprocess technology. Dr. Aunins earned his Ph.D. in chemical engineering from MIT in 1989 under Institute Professor Daniel I.C. Wang.

Day Two

Wednesday, 31st January 2018

09.00 | Panel Presentation: Manufacturing the Microbiome - An Industry Perspective

David Cook
EVP of R&D and Chief Scientific Officer
Seres Therapeutics

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres. He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.

Day One

Tuesday, 30th January 2018

09.00 | Studying Microbiome-Host Interactions to Translate Microbiome Drugs into the Clinic

Richard Schwartz
SVP Process Development and Manufacturing
Synlogic

Dr. Richard Schwartz joined Synlogic in September 2016 as senior vice president of process development and manufacturing, where he is responsible for the oversight and management of process development and manufacturing of Synlogic’s product candidates. Previously, Richard was the chief of the Vaccine Production Program (VPP) at the Vaccine Research Center (VRC) at the NIAID/NIH. At the VRC, he was responsible for development and clinical production of vaccines against viruses which include HIV, Ebola, Zika, Influenza, Chikungunya and Equine Encephalitis, as well as the first broadly neutralizing monoclonal antibody against HIV. Richard has 30 years of experience in pharma and biotech working in diverse areas including pharmaceutical natural product production, hematopoietic stem cells, vaccines and therapeutic proteins. Richard was previously the senior director of process and manufacturing sciences at MedImmune Vaccines (formerly Aviron), where he was responsible for vaccine development and clinical manufacturing of new vaccine candidates, as well as for providing support to commercial vaccine manufacturing operations. Additionally, he was team lead for a BARDA-funded development effort to convert FluMist from an egg-based to a cell culture--based production process. Prior to MedImmune, Richard worked at SyStemix, Aastrom Biosciences and Eli Lilly. Richard received his bachelor’s degree, master’s degree and Ph.D. in chemical engineering from the University of Michigan.

Day Two

Wednesday, 31st January 2018

09.00 | Panel Presentation: Manufacturing the Microbiome - An Industry Perspective

Todd Parsley
Chief Scientific Officer
SynPhaGen, LLC

Todd obtained his B.A. in Microbiology from University of California, San Diego, and a Ph.D. in Microbiology and Molecular Genetics from University of California, Irvine. Todd has more than 25 years’ experience in academia and the private sector with extensive expertise in molecular biology and microbiology. He has authored several peer-review publications and has been a primary investigator on NIH-funded grants. He is currently a member of the America Society of Microbiology and the International Society for Antiviral Research. Prior to joining SynPhaGen, he was a director of Molecular Virology and Microbiology at a contract research organization for over 10 years where he directed multiple research programs focused on pathogen host interactions, viral replication/gene expression and pathogen resistance. He also directed the development of novel anti-infective therapies.

Christian Freguia
Director of Research
Synthetic Biologics

Day One

Tuesday, 30th January 2018

15.20 | Clinical Development of Ribaxamse, an Oral-Beta Lactamase Intended to Protect the Gut Microbiome and Prevent C.Diificile

Gregory Lambert
CEO and VP R&D
TargEDys

Gregory LAMBERT carrier is split between biotech and pharma where he occupied the jobs of VP R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities covered innovation,  CMC, pre-clinical and Clinical development in Europe and north America. He was also in charge of the IP, involved in the Business development and general manager.  Gregory is inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he drove the development several pharmaceutical products from the laboratory to market authorizations. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations.

Day One

Tuesday, 30th January 2018

17.40 | Panel Presentation: Overcoming Regulatory Uncertainty to Accelerate Speed to Market

Bernhard Paetzold
Chief Scientific Officer
S-Biomedic

Bernhard completed his Ph.D. in synthetic biology, working together in collaboration with the pharmaceutical industry to engineer bacteria as a living pill. He is a scientific co-founder of S-Biomedic, and is leading the research and product development. His passion is understanding the complex interplay of the bacterial communities that live within and on us. He is fascinated by the untouched potential of active compounds that are naturally produced every day right on our own skin.

Larry Weiss
Chief Medical Officer
AOBiome

Larry Weiss MD is the Chief Medical Officer at AOBiome. He has an extensive background in natural products chemistry, microbiology, clinical medicine, and pharmaceutical development and product commercialization. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University Medical School, and a BS from Cornell University in Biochemistry. He has a multiple patents and is published in the areas of chemistry, electrophysiology, pharmacology, and microbiology. Dr. Weiss is the founder of CleanWell Company.

Rita Colwell
Distinguished Professor
University of Maryland

Day One

Tuesday, 30th January 2018

10.30 | Microbiome in Understanding Human Biology, Disease and Diagnostics

Travis Whitfill
Co-Founder and Chief Scientific Officer
Azitra Inc.

Manoj Dadlani
CEO
CosmosID

Day One

Tuesday, 30th January 2018

10.50 | Presentation to be Confirmed: Please Check Back with us Soon

Dirk Gevers
Global Head, JHMI
Janssen Research and Development

Day Two

Wednesday, 31st January 2018

15.20 | Panel Presentation: Committing to the Therapeutic Potential of the Microbiome - Resources for Results

Arpita Maiti
Senior Director, ERDI I&I
Pfizer

Mike Frodsham
Pharmaceutical Development Manager
Quay Pharma

Day Two

Wednesday, 31st January 2018

10.10 | Oral Delivery of Live Bio-Therapeutics: Drug Product Development for FIM Studies

Bruce Roberts
Chief Scientific Officer
Vedanta Biosciences

Day One

Tuesday, 30th January 2018

16.20 | Clinical Considerations of Rationally Designed Live Bacterial Cocktails

Henry Haiser
Investigator III
Novartis Institutes of Biomedical Research

Day One

Tuesday, 30th January 2018

12.30 | Microbiome Research at NIBR: Microbial Metabolites That Modulate Host Functions

Day Two

Wednesday, 31st January 2018

15.20 | Panel Presentation: Committing to the Therapeutic Potential of the Microbiome - Resources for Results

Confirmed Company
TBA
4D Pharma PLC

Thomas Kuri
Scientific Director
Zymo Research

Day One

Tuesday, 30th January 2018

13.00 | Standardizing Microbiomics – Removing Bias in Collection, Purification and Analyses

Tina Christensen Ram
Head of Quality
Luina Bio

Day Two

Wednesday, 31st January 2018

10.00 | Quality and GMP Aspects of Manufacturing Live Biotherapeutic Products - a CMO Quality Perspective

Mike Romanos
CEO
Microbiotica

Day Two

Wednesday, 31st January 2018

12.10 | Precision Discovery of Novel Bacterial Therapeutics and Biomarkers Based on Deep Microbiome Analysis